Skip to main content
. 2019 Sep 9;19(3):17. doi: 10.5334/ijic.4675

Table 2.

Checklist assessing the quality of economic evaluations.

Category Item Description Zulman et al. (2017) Weisner et al. (2001) Weeks et al. (2009) Weaver et al. (2009) Van Orden et al. (2009) Olsson et al. (2009) Leeuwen et al. (2015) Lanzeta et al. (2016) Goorden et al. (2013) Boland et al. (2015) Donohue et al. (2014) Cohen et al. (2012) Wise et al. (2006) McCall et al. (2010) Simon et al. (2001) Hebert et al. (2008) Vroomen et al. (2012) Salmon et al. (2012) Looman et al. (2016) Celano et al. (2016) Markle-Reid et al. (2010) Pozzilli et al. (2002) Tzeng et al. (2007) Bergmann et al. (2017) Koch et al. (2017) Rosenheck et al. (2016) Sahlen et al. (2016) Blom et al. (2016) Pimperl et al. (2017) Schellenberg et al. (2004) Bird et al. (2012) Goltz et al. (2013) Steuten et al. (2007) Wiley-Exley et al. (2009) Karow et al. (2012) Renaud et al. (2009) Tanajewski et al. (2015) Lambeek et al. (2010) Bertelsen et al. (2017) Camacho et al. (2018) Everink et al. (2018) Kam et al. (2018) Ulttenbroek et al. (2018) Tsiachristas et al. (2015) %

Study design 1. Design was experimental (e.g. RCT or cluster-RCT) or quasi experimental design (e.g. used propensity score matching, pretest-posttest design)? 75
2. Random allocation into intervention and control groups 57
3. The study population consist of an intervention and control group Y 91
4. Relevant baseline characteristics are comparable NA 72
5. The interventions or strategies being compared are described 98
6. Included more than just baseline and follow up period 61
7. Clear description of inclusion and exclusion 86
8. Clear description of drop-outs 70
Intervention setting 9. Stated relevant aspects of the system(s) in which intervention takes place 84
10. Co-interventions or contamination are avoided 32
Measurement of costs & outcomes 11. Describe the perspective of the study and relate this to the outcomes and costs being evaluated. 75
12. Described which outcomes were used as the measure(s) of benefit in the evaluation 100
13. Inclusion of development and implementation cost 34
14. Inclusion of cost & utilization from across all relevant health and social sectors 66
15. Inclusion of direct non-medical and indirect costs 39
16. Justification for omitting costs categories N/A NA NA NA NA NA 29
17. The sources of resource utilization and cost are described 91
18. The resource utilization and costs are reported separately 75
19. Reports the (adjusted) dates of estimated resource quantities and unit costs Y Y Y Y Y 73
20. Discounting of outcomes and costs performed NA NA Y NA NA NA NA Y NA NA NA NA NA NA NA NA Y NA NA Y NA N/A NA NA NA NA 18
Statistical analysis 21. Data analysis is performed according intention-to-treat principle 39
22. Dealt adequately with missing observations 59
23. Appropriate statistical methods for analysing skewed data 68
24. Report the values, ranges, references, and if used, probability distributions for all parameters. 91
25. Analysed cost-effectiveness using the incremental cost- effectiveness ratio (ICER) method 55
26. Analysed cost-effectiveness using the incremental net- monetary or health benefit (INB) regression method 7
27. Performed sub group analysis to examine heterogeneity of results 48
28. Analysed the uncertainty in the estimates of the costs and effects 64
Presentation of data 29. A decision criteria is applied to determine whether to reject or accept intervention (e.g. willingness-to-pay vs. cost effectiveness threshold) 43
30. The study discusses the generalizability of the results to other context and/or patient groups 98

Legend: yes ✓, no ○.